Newsoara licenses oncolytic virus from Genelux in $171M deal
Sarina Yang ·2 months ago

Newsoara BioPharma obtained exclusive rights to Olvi-Vec, an oncolytic virus drug in clinical phase II, from Genelux in a deal worth up to $171 million.

Genelux will receive $11 million upfront and up to $160 million in milestone payments, as well as tiered royalties sales.

Newsoara will have exclusive rights to Olvi-Vec in Greater China and will also have exclusive rights to Genelux's oncolytic virus platform. The two companies will also collaborate on a Phase II clinical trial of Olvi-Vec in a new intravenous indication in China and the U.S., with Newsoara being responsible for all trial costs.

Genelux plans to conduct a Phase III registration trial in the U.S. for platinum-resistant/refractory ovarian cancer. According to Genelux’s website, indications under development for OLVI-VEC include ovarian cancer and non-small cell lung cancer.

Keywords: Newsoara $171M Genelux oncolytic virus
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement